Small Biotech Teams Up with Major OTC Cosmetic Provider

Biotech's Next Big Giant?...& ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from i2i Marketing Dear Reader, You've just stumbled upon a tiny $10 million biotech about to team up with an absolute powerhouse in the OTC cosmetics sector... And it's set to go public on the NASDAQ just days from now. They've discovered how to cure scaring from the human body. And this tiny biotech is now in talks with MAJOR, global brands for an over-the-counter product that could be the next big thing for cosmetics.. But its applications go far beyond that... They're able to prevent up to 45% of deaths in the world. And could CURE autoimmune diseases like Type 1 diabetes. That's why it won't be a surprise when a major Big Pharma player also partners up with them in the future... potentially Johnson and Johnson or Pfizer. With one stroke of their pen, they could have their accountants buy out this little biotech. Or simply sign a check for all the supplies of this treatment they could ever want. And with the FDA approving more treatments than ever and nothing else on the planet like this, it won't be a surprise to see this company hit moonshot potential before it lists on the NASDAQ. You can get in before that happens. Right now you can get in... before this partnership not only validates this company's innovative approach but also positions the company for rapid growth and market penetration as they go public. (Even if you're not accredited, you can use this rare investment backdoor - and get in for as little as $1,000). The implications of this partnership are enormous, as you're about to see. Best, Editor This message is a PAID ADVERTISEMENT for BirchBioMed Inc. (Reg A+) from i2i Marketing Group, LLC. StockEarnings, Inc. has received a fixed fee of $5,000 from i2i Marketing Group, LLC. for multiple Dedicated Email Sends, Newsletter Sponsorships, SMS Sends, and Banner Display Ads between November 18, 2024 and November 28, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BirchBioMed Inc. (Reg A+) or i2i Marketing Group, LLC. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BirchBioMed Inc. (Reg A+) on BirchBioMed website for additional information about the relationship between i2i Marketing Group, LLC. and BirchBioMed Inc. (Reg A+). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com